#PCOS #GLP1 #PMOS #Semaglutide #Tirzepatide
Not losing weight on GLP-1 with PCOS? You're not imagining it, and it's not a willpower problem. In this video, I explain why semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) can stall in women with PCOS, now officially renamed PMOS (polyendocrine metabolic ovarian syndrome), and the 4 things doctors do to get weight loss moving again.
You'll learn the 3 hormonal roadblocks behind a PCOS stall (high insulin, androgens and belly fat, and your own GLP-1 system), why standard dosing often isn't enough, how tirzepatide compares with semaglutide, when metformin or inositol makes sense, which labs to track (fasting insulin, HOMA-IR, free testosterone, SHBG, TSH, A1c and lipids), and how to tell your treatment is working even when the scale isn't.
๐ Complete GLP-1 Weight Loss Masterclass โ Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com
๐ฉ FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter
Timestamps
00:00 Why GLP-1 weight loss stalls with PCOS
00:55 About me
01:21 PCOS is now PMOS: why the name changed
02:36 Insulin resistance in PCOS: the numbers
03:12 Roadblock #1: Hyperinsulinemia
04:44 Roadblock #2: Androgens and belly fat
06:10 Muscle: a shortcut around insulin resistance
06:57 Roadblock #3: Your own GLP-1 system
07:55 Why standard GLP-1 dosing stalls
09:11 Metabolic adaptation and normal plateaus
09:51 Fix #1: Right drug, right dose
10:36 Tirzepatide vs semaglutide (and PCOS data)
11:39 Retatrutide
11:56 Pregnancy and birth control on GLP-1s
12:22 Fix #2: Metformin, combination therapy and inositol
13:57 Fix #3: Labs to track, not just the scale
15:33 Fix #4: Body composition and protecting muscle
16:39 Non-scale wins to watch
17:09 GLP-1 Masterclass
17:30 Summary and what happens if you stop
References
1. Teede HJ, et al. 2023 International Evidence-based Guideline for PCOS. J Clin Endocrinol Metab. 2023;108(10):2447-2469.
2. PCOS renamed PMOS. The Lancet, May 12, 2026; Monash/MCHRI terminology summary, 2026.
3. Stepto NK, et al. Hum Reprod. 2013;28(3):777-784.
4. Cassar S, et al. Hum Reprod. 2016;31(11):2619-2631.
5. Nestler JE. Semin Reprod Endocrinol. 1997;15(2):111-122.
6. O'Reilly MW, et al. J Clin Endocrinol Metab. 2017;102(9):3327-3339.
7. Zhu S, et al. Front Endocrinol. 2021;12:697223.
8. Karolinska Institutet doctoral thesis on adipocyte lipolysis in PCOS.
9. Moro C, et al. J Clin Endocrinol Metab. 2009;94(7):2579-2586.
10. Aydin K, et al. Clin Endocrinol. 2014;81(4):588-592.
11. Gรผneลli I, et al. Endocrine Abstracts. 2025;110:RC5.2.
12. An impaired GLP-1 response is associated with prediabetes in PCOS with obesity. PMC6833370.
13. Glintborg D, et al. Endocr Connect. 2017;6(4):267-277.
14. Wegovy (semaglutide) US Prescribing Information, including Wegovy HD 7.2 mg (FDA, 2026).
15. Zepbound (tirzepatide) US Prescribing Information.
16. Carmina E, Longo RA. J Clin Med. 2023;12(18):5921.
17. Alawami F, et al. Ir J Med Sci. 2026;195(1):131-136.
18. Fothergill E, et al. Obesity. 2016;24(8):1612-1619.
19. Thomas MK, et al. J Clin Endocrinol Metab. 2021;106(2):388-396.
20. Tirzepatide vs semaglutide on beta-cell function and insulin sensitivity. J Clin Endocrinol Metab. 2024;109(12):3046-3054.
21. Aronne LJ, et al. SURMOUNT-5. N Engl J Med. 2025;393(1):26-36.
22. Clift AK, et al. J Endocr Soc. 2026;10(9):bvag177.
23. PERIODS trial (tirzepatide in PCOS). ClinicalTrials.gov NCT07326111.
24. Jastreboff AM, et al. TRIUMPH-1 (retatrutide). N Engl J Med. 2026.
25. Jensterle M, et al. Exp Ther Med. 2016;11(4):1194-1200.
26. Zhang W, et al. Metab Target Organ Damage. 2026;6:10.
27. Fitz V, et al. J Clin Endocrinol Metab. 2024;109(6):1630-1655.
28. Matthews DR, et al. Diabetologia. 1985;28(7):412-419.
29. Ding X, et al. Front Endocrinol. 2018;9:700.
30. Wilding JPH, et al. STEP 1. N Engl J Med. 2021;384:989-1002; Jastreboff AM, et al. SURMOUNT-1. N Engl J Med. 2022;387:205-216.
31. Jensterle M, et al. Front Endocrinol. 2024;15:1366940.
โ๏ธ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.